Berlin, Germany, November 27, 2019. After successfully introducing its prostate seed and ophthalmic brachytherapy product portfolio to Brazil, Eckert & Ziegler BEBIG is now extending its product range with the SagiNova® HDR afterloader system.
Eckert & Ziegler BEBIG´s SagiNova® HDR Afterloader
After receiving the market clearance by Agência Nacional de Vigilância Sanitária (ANVISA) earlier this fall and following a first glance at this year´s XXI Congresso da Sociedade Brasileira de Radioterapia, SagiNova® is now actively being offered to Brazil’s Radiation Oncology Centers.
The successor of Eckert & Ziegler BEBIG´s MultiSource afterloader, which entered the Brazilian market in 2013, is available with a long-lasting, miniaturized cobalt-60, or a well-established iridium-192 source. As regards cobalt-60, Eckert & Ziegler BEBIG can proudly boast over 290 running systems worldwide. This source type can be considered particularly interesting for Brazil, due to the country´s demanding logistics. The SagiNova® system is completed by the SagiPlan® treatment planning system, with its exclusive inverse irradiation planning with DVH, BED, EQD2 and an integrated prostate module, as well as a broad applicator portfolio, including Mick Radio-Nuclear Instruments’ gynecological and prostate applicators.
Brazil records over 550,000 new cancer cases each year with breast, prostate, and lung ranking among the highest incidences. The number of cancer deaths can be considered high, with about 240,000 in 2018.*
About HDR brachytherapy
HDR brachytherapy enables radiation oncologists to deliver the radiation quickly, most often as an outpatient procedure. During this procedure, a computer driven apparatus, known as a remote afterloading device, pushes the radioactive source attached to a drive wire through transfer tubes and applicators to the treatment site. The radioactive source can be moved in millimeter increments and remain in a certain position (dwell position) for a predetermined amount of time to optimize the delivered dose. When the desired treatment dose has been achieved, the remote afterloading device automatically withdraws the radioactive source so that there is no residual radiation or radioactivity.
HDR brachytherapy has been used since the 1960s and is currently applied to treat cancers in areas of the body such as gynecological, rectal, prostate and breast areas. The procedure enables an accurate and precise tumor-specific radiation dose delivery in a shorter course of treatment compared with other types of radiation treatment methods, while preserving the structure and function of the treated and neighboring organ(s).
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a global provider of radiotherapy products and a leader in brachytherapy in Europe. The company’s offices and subsidiaries are located throughout Europe, Asia, and the United States. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product lines. In recent years, Eckert & Ziegler BEBIG has grown through the acquisitions of US-based Mick Radio-Nuclear Instruments, Inc. and the x-ray device manufacturer WOLF-Medizintechnik GmbH (WOmed). Eckert & Ziegler BEBIG is the oldest subsidiary of the Eckert & Ziegler Group. The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific, and industrial use. The core businesses of the Group are cancer therapy, industrial radiometry, and nuclear-medical imaging.
Marketing Communication Manager